Article Text

News in brief

Statistics from

Monoclonal antibody receives European authorisation

Zoetis has been granted a marketing authorisation in the European Union for Cytopoint, its monoclonal antibody therapy for the treatment of atopic dermatitis in dogs. Earlier this year the European Medicines Agency's Committee for Medicinal Products for Veterinary Use recommended to the European Commission that the product, which contains a new active substance, lokivetmab, should be …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.